Please refer to Phase I studies for more clinical trial opportunities

Melanoma

Adjuvant Therapies

Stage 2b or 2c

IRB#16679
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

Stage 2b, 2c or 3

IRB#11848
Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

Stage 3 or 4 Resectable

IRB#15661
A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

IRB#16883
A Phase III, Randomized Study of Nivolumab with Ipilimumab vs. Ipilimumab or Nivolumab Monotherapy Post-resection

Modern
A Phase II randomized study of adjuvant Immunotherapy with Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

CROSS-DISEASE TRIALS:

IRB# TBD
EAY131 (MATCH)

IRB# TBD
S1609 (DART)

Observational

IRB#17104
DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study

Uveal Melanoma

IRB#16162:
A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

http://www.ohsu.edu/research/rda/so/knight.php
<table>
<thead>
<tr>
<th>IRB#</th>
<th>Study Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16198</td>
<td>A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides</td>
<td>Phase 1 dose escalation trial for TTI-621 in subjects with melanoma.</td>
</tr>
<tr>
<td>18687</td>
<td>A phase 3, randomized, open-label study of NKTR-214 combined with nivolumab versus nivolumab in participants with previously untreated unresectable or metastatic melanoma.</td>
<td>Phase 3 study comparing NKTR-214 with nivolumab in melanoma patients.</td>
</tr>
<tr>
<td>19207</td>
<td>A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib(E7080/Mk-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)</td>
<td>Phase III study evaluating pembrolizumab with or without lenvatinib.</td>
</tr>
<tr>
<td>19943</td>
<td>A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma</td>
<td>Phase II study comparing RO7198457 with pembrolizumab in melanoma.</td>
</tr>
<tr>
<td>19285</td>
<td>A Phase Ib/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma</td>
<td>Phase Ib/2 study evaluating PV-10 for metastatic melanoma.</td>
</tr>
</tbody>
</table>